Fundraising FoxSanofi Ventures — 2025 Investments
12 investments dated 2025 · listed companies and verified rows first · show all
Character Bio is a patient-driven therapeutics company that combines genomics, longitudinal clinical and imaging data, and machine learning to identify genetic drivers of disease progression and develop new treatments, with a focus on polygenic diseases.
AI & Machine LearningBiotechDigital HealthJersey City, US
Cheng Zhang(CEO, Co-Founder)inMarcel van der Brug(Scientific Advisor, Co-Founder)inNick Johnson(Technology Advisor, Co-Founder)inDaniel Elgort(Chief Data and Analytics Officer)inLaura Carter(Chief Scientific Officer)inRobert Kim(Chief Medical Officer)in
Co-investorsaMoonLuma GroupInnovation EndeavorsCantos VenturesCatalio Capital Management, LPDuke Capital Partners+5 more
Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.
BiotechMedical DevicesBasel, CH
Patrick Loustau(President and Chief Executive Officer)in
Co-investorsNovartis Venture FundForbionVersant Ventures
Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.
BiotechDeep TechHealthtechBurlington, MA, US
Jay Rothstein, Ph.D.(Scientific Co-Founder and Advisor)Arthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)Arthur Tzianabos, Ph.D.(President & Chief Executive Officer)
Co-investorsARCH Venture PartnersAtlas Venture5AM Ventures
Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.
BiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)inWilliam LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)
Co-investorsTaiho Ventures, LLCPfizer VenturesSamsara BioCapitalCanaan PartnersConnecticut InnovationsOUP (Osage University Partners)+6 more
SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.
BiotechDeep TechDigital HealthBarcelona, ES
Dr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)
Co-investorsAsabys PartnersNovartis Venture FundRoche Venture FundYsios CapitalCriteria Bio VenturesNew Enterprise Associates (NEA)+3 more
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)inMichelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)inGary Patou(Executive Officer)in
Board seatJason P. Hafler· per SEC Form D
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSofinnova VenturesViking GlobalAgent Capital+11 more
Atalanta is developing treatment options for intractable central nervous system diseases using RNA interference technology.
BiotechDeep TechHealthtechMedical Devices
Co-investorsF-Prime CapitalNovartis Venture FundRiverVest Venture Partnersabrdn plcEQT Life Sciences
Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases.
BiotechHealthtech
George Simeon(CEO)inGregory S. Curhan(CFO)Guy De La Rosa(CMO)in
Co-investorsAdjuvant CapitalOrbiMedRA CapitalHBM Healthcare InvestmentsJanus Henderson InvestorsMedicxi
Enveda operates a drug-discovery platform that analyzes natural samples—primarily plant-derived molecules—using mass spectrometry, AI foundation models, and automated high-throughput labs to identify their chemical structures and therapeutic properties.
AI & Machine LearningBiotechDeep TechBoulder, US
Viswa Colluru(Founder)inDaniel Wee(Executive Officer)Pieter Dorrestein(Founder)Viswa Colluru Pieter Dorrestein(Founder)
BoardRohit Sharma(Director)Zavain Dar(Director)in
Co-investorsAir Street CapitalBoulder VenturesCatalio Capital Management, LPCox EnterprisesFPVGaingels+21 more
__Twitter.png)
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk.
BiotechHealthtechMedical DevicesThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)Sean Harper Desmond Padhi(Founder)
BoardBeth Seidenberg(Director)inJim Tananbaum(Director)inDeborah Palestrant(Director)in
Co-investors5AM VenturesAccess BiotechnologyAscenta CapitalForesite CapitalKern Capital, LLCWestlake Village BioPartners
QuantHealth provides clinical trial design optimization tools that help pharmaceutical and biotech companies evaluate trial outcomes, competitive positioning, and enrollment feasibility to reduce development risk and accelerate timelines.
AI & Machine LearningBiotechDigital HealthHealthtech
Orr Inbar(Founder)inArnon Horev(Founder)inOrr Inbar Arnon Horev(Founder)
Co-investorsIsrael Innovation AuthorityATOORO FUNDEsplanade VenturesNina CapitalNovaCapitalPitango+1 more
Trial Library operates an AI-native platform that integrates clinical trials into routine care, activating providers, identifying eligible patients, and guiding them through the trial lifecycle.
AI & Machine LearningDigital HealthHealthtech
Co-investorsGaingelsHow Women InvestLux CapitalNext VenturesOverwater Ventures LlcPlug and Play Ventures+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.